{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":4,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05171777\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["subcutaneous atezolizumab"]],"indication":"non-small cell lung cancer","name":"IMscin002","nct_id":"NCT05171777","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imscin002-nct05171777. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive atezolizumab SC followed by atezolizumab IV.","label":"Treatment A","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab IV followed by atezolizumab SC.","label":"Treatment B","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-10-25","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":179,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"}],"last_update":"2025-12-11","lead_sponsor":"Hoffmann-La Roche","official_title":"A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-11-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ)","timeFrame":"Cycle 6 Day 1 (cycle length=21 days)"}],"references":[{"citation":"Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Felip E, Majem M, Korbenfeld E, Kolb-Sielecki J, Isla D, Barata T, Bustillos A, Herraez-Baranda LA, Tosti N, Young F, Zanghi J, Cappuzzo F. Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. Lung Cancer. 2026 Jul;217:109452. doi: 10.1016/j.lungcan.2026.109452. Epub 2026 May 12.","pmid":"42214243","type":"DERIVED"},{"citation":"Majem M, Chewaskulyong B, Zvirbule Z, Lee KH, Korbenfeld E, Kolb-Sielecki J, Castro Sanchez AY, Bustillos A, Herraez-Baranda L, Liu X, Kim SW, Cappuzzo F. Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer. Oncol Ther. 2026 Mar;14(1):313-326. doi: 10.1007/s40487-025-00402-x. Epub 2025 Nov 26.","pmid":"41296193","type":"DERIVED"}],"start_date":{"date":"2022-04-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05171777"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imscin002-nct05171777"}